

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



山東威高集團醫用高分子製品股份有限公司
Shandong Weigao Group Medical Polymer Company Limited *

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

PROPOSED ADOPTION OF THE 2025 H SHARE INCENTIVE SCHEME

The board (the “**Board**”) of directors (the “**Directors**”) of Shandong Weigao Group Medical Polymer Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Board has resolved to approve the proposed adoption of a H share incentive scheme (the “**2025 H Share Incentive Scheme**”) of the Company.

The purposes of the 2025 H Share Incentive Scheme are to: (i) attract and retain eligible participants whose contributions are important to the long-term growth and success of the Group, and to recognize and reward eligible participants for their past contributions to the Group; (ii) encourage eligible participants to further contribute to the Company and work towards enhancing the value of the Company and its shares (the “**Shares**”) for the benefit of the Company and its shareholders (the “**Shareholders**”) as a whole; (iii) enhance the Company’s long-term remuneration incentive strategy; and (iv) to align the interests of the eligible participants with those of the Company and the Shareholders to promote the long-term performance (whether in financial, business and operational aspects) of the Group.

* For identification purpose only

The Board (including the independent non-executive Directors) believes that the adoption of the 2025 H Share Incentive Scheme helps to realize the aforesaid goals and is in the interests of the Company and the Shareholders as a whole.

Pursuant to the articles of association of the Company, the adoption of the 2025 H Share Incentive Scheme and related matters are subject to, among other things, the approval of the Shareholders at a general meeting of the Company.

The 2025 H Share Incentive Scheme is intended to be funded by existing H shares of the Company and/or treasury shares (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)) of the Company. Therefore, the adoption of the 2025 H Share Incentive Scheme is subject to the approval of the Shareholders pursuant to Chapter 17 of the Listing Rules.

An extraordinary general meeting (the “**EGM**”) of the Company will be convened and held to consider and, if thought fit, approve, among other things, the proposed adoption of the 2025 H Share Incentive Scheme. A circular containing, among other things, details and principal terms of the 2025 H Share Incentive Scheme together with a notice of the EGM will be published by the Company in due course in accordance with the Listing Rules.

By order of the Board
Shandong Weigao Group Medical Polymer Company Limited
Long Jing
Chairman

Weihai, Shandong, the PRC, 27 August 2025

As at the date of this announcement, the Board comprises:

Mr. Long Jing (*Executive Director*)

Mr. Cong Rinan (*Executive Director*)

Mr. Lu Junqiang (*Executive Director*)

Mr. Wang Daoming (*Executive Director*)

Ms. Yan Xia (*Non-executive Director*)

Mr. Chen Lin (*Non-executive Director*)

Mr. Tang Zhengpeng (*Non-executive Director*)

Mr. Li Guohui (*Independent Non-executive Director*)

Mrs. Meng Hong (*Independent Non-executive Director*)

Mr. Li Qiang (*Independent Non-executive Director*)

Mr. Sun Heng (*Independent Non-executive Director*)